These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17115114)

  • 1. Frequent loss of Dab2 protein and infrequent promoter hypermethylation in breast cancer.
    Bagadi SA; Prasad CP; Srivastava A; Prashad R; Gupta SD; Ralhan R
    Breast Cancer Res Treat; 2007 Sep; 104(3):277-86. PubMed ID: 17115114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
    Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
    Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
    Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
    Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
    Jiang Y; Tong D; Lou G; Zhang Y; Geng J
    Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.
    Sathyanarayana UG; Padar A; Huang CX; Suzuki M; Shigematsu H; Bekele BN; Gazdar AF
    Clin Cancer Res; 2003 Dec; 9(17):6389-94. PubMed ID: 14695139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation.
    Zhao C; Lam EW; Sunters A; Enmark E; De Bella MT; Coombes RC; Gustafsson JA; Dahlman-Wright K
    Oncogene; 2003 Oct; 22(48):7600-6. PubMed ID: 14576822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disabled-2 inactivation is an early step in ovarian tumorigenicity.
    Fazili Z; Sun W; Mittelstaedt S; Cohen C; Xu XX
    Oncogene; 1999 May; 18(20):3104-13. PubMed ID: 10340382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A tumor-protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to-mesenchymal transition.
    Pampalakis G; Prosnikli E; Agalioti T; Vlahou A; Zoumpourlis V; Sotiropoulou G
    Cancer Res; 2009 May; 69(9):3779-87. PubMed ID: 19383923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation.
    Evron E; Umbricht CB; Korz D; Raman V; Loeb DM; Niranjan B; Buluwela L; Weitzman SA; Marks J; Sukumar S
    Cancer Res; 2001 Mar; 61(6):2782-7. PubMed ID: 11289162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
    Potapova A; Hoffman AM; Godwin AK; Al-Saleem T; Cairns P
    Cancer Res; 2008 Feb; 68(4):998-1002. PubMed ID: 18281473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
    Baldwin RL; Nemeth E; Tran H; Shvartsman H; Cass I; Narod S; Karlan BY
    Cancer Res; 2000 Oct; 60(19):5329-33. PubMed ID: 11034065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermediate filament dynamics and breast cancer: aberrant promoter methylation of the Synemin gene is associated with early tumor relapse.
    Noetzel E; Rose M; Sevinc E; Hilgers RD; Hartmann A; Naami A; Knüchel R; Dahl E
    Oncogene; 2010 Aug; 29(34):4814-25. PubMed ID: 20543860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational, epigenetic and expressional analyses of caveolin-1 gene in breast cancers.
    Chen ST; Lin SY; Yeh KT; Kuo SJ; Chan WL; Chu YP; Chang JG
    Int J Mol Med; 2004 Oct; 14(4):577-82. PubMed ID: 15375584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing of LRRC49 and THAP10 genes by bidirectional promoter hypermethylation is a frequent event in breast cancer.
    De Souza Santos E; De Bessa SA; Netto MM; Nagai MA
    Int J Oncol; 2008 Jul; 33(1):25-31. PubMed ID: 18575747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.
    Veeck J; Chorovicer M; Naami A; Breuer E; Zafrakas M; Bektas N; Dürst M; Kristiansen G; Wild PJ; Hartmann A; Knuechel R; Dahl E
    Oncogene; 2008 Jan; 27(6):865-76. PubMed ID: 17653090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restoration of positioning control following Disabled-2 expression in ovarian and breast tumor cells.
    Sheng Z; Sun W; Smith E; Cohen C; Sheng Z; Xu XX
    Oncogene; 2000 Oct; 19(42):4847-54. PubMed ID: 11039902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular events associated with dysplastic morphologic transformation and initiation of ovarian tumorigenicity.
    Yang DH; Smith ER; Cohen C; Wu H; Patriotis C; Godwin AK; Hamilton TC; Xu XX
    Cancer; 2002 May; 94(9):2380-92. PubMed ID: 12015763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypermethylation does not account for the frequent loss of the retinoic acid receptor beta2 in breast carcinoma.
    Yang Q; Sakurai T; Yoshimura G; Mori I; Nakamura M; Nakamura Y; Suzuma T; Tamaki T; Umemura T; Kakudo K
    Anticancer Res; 2001; 21(3B):1829-33. PubMed ID: 11497266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis.
    Capo-Chichi CD; Smith ER; Yang DH; Roland IH; Vanderveer L; Cohen C; Hamilton TC; Godwin AK; Xu XX
    Cancer; 2002 Oct; 95(8):1802-15. PubMed ID: 12365030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer.
    Zhang Z; Huettner PC; Nguyen L; Bidder M; Funk MC; Li J; Rader JS
    Oncogene; 2006 Aug; 25(39):5436-45. PubMed ID: 16607278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.